

Rheumatoid Arthritis

## Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

<b>Trial Status</b> Completed	<b>Trial Runs In</b> 1 Countries	<b>Trial Identifier</b> NCT02608112 ML29256
----------------------------------	-------------------------------------	--

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).

<b>Hoffmann-La Roche</b> Sponsor	<b>N/A</b> Phase
-------------------------------------	---------------------

---

<b>NCT02608112 ML29256</b> Trial Identifiers
---

---

### *Eligibility Criteria:*

<b>Gender</b> All	<b>Age</b> >= 18 Years	<b>Healthy Volunteers</b> No
----------------------	---------------------------	---------------------------------

---